Literature DB >> 18227167

Transcutaneous immunization with cross-reacting material CRM(197) of diphtheria toxin boosts functional antibody levels in mice primed parenterally with adsorbed diphtheria toxoid vaccine.

Paul Stickings1, Marisa Peyre, Laura Coombes, Sylviane Muller, Rino Rappuoli, Giuseppe Del Giudice, Charalambos D Partidos, Dorothea Sesardic.   

Abstract

Transcutaneous immunization (TCI) capitalizes on the accessibility and immunocompetence of the skin, elicits protective immunity, simplifies vaccine delivery, and may be particularly advantageous when frequent boosting is required. In this study we examined the potential of TCI to boost preexisting immune responses to diphtheria in mice. The cross-reacting material (CRM(197)) of diphtheria toxin was used as the boosting antigen and was administered alone or together with either one of two commonly used mucosal adjuvants, cholera toxin (CT) and a partially detoxified mutant of heat-labile enterotoxin of Escherichia coli (LTR72). We report that TCI with CRM(197) significantly boosted preexisting immune responses elicited after parenteral priming with aluminum hydroxide-adsorbed diphtheria toxoid (DTxd) vaccine. In the presence of LTR72 as an adjuvant, toxin-neutralizing antibody titers were significantly higher than those elicited by CRM(197) alone and were comparable to the functional antibody levels induced after parenteral booster immunization with the adsorbed DTxd vaccine. Time course study showed that high levels of toxin-neutralizing antibodies persisted for at least 14 weeks after the transcutaneous boost. In addition, TCI resulted in a vigorous antigen-specific proliferative response in all groups of mice boosted with the CRM(197) protein. These findings highlight the promising prospect of using booster administrations of CRM(197) via the transcutaneous route to establish good herd immunity against diphtheria.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18227167      PMCID: PMC2292886          DOI: 10.1128/IAI.00797-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

Review 1.  Modulation of immune responses with transcutaneously deliverable adjuvants.

Authors:  Charalambos D Partidos; Anne-Sophie Beignon; Jean-Paul Briand; Sylviane Muller
Journal:  Vaccine       Date:  2004-06-23       Impact factor: 3.641

2.  Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan.

Authors:  Edel A McNeela; Inderjit Jabbal-Gill; Lisbeth Illum; Mariagrazia Pizza; Rino Rappuoli; Audino Podda; David J M Lewis; Kingston H G Mills
Journal:  Vaccine       Date:  2004-02-25       Impact factor: 3.641

Review 3.  Aluminium adjuvants--in retrospect and prospect.

Authors:  Erik B Lindblad
Journal:  Vaccine       Date:  2004-09-09       Impact factor: 3.641

Review 4.  New adjuvants: EU regulatory developments.

Authors:  Dorothea Sesardic; Sjoerd Rijpkema; Brijesh Prakash Patel
Journal:  Expert Rev Vaccines       Date:  2007-10       Impact factor: 5.217

5.  The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197.

Authors:  G Giannini; R Rappuoli; G Ratti
Journal:  Nucleic Acids Res       Date:  1984-05-25       Impact factor: 16.971

6.  Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin.

Authors:  Frances Bowe; Ed C Lavelle; Edel A McNeela; Christine Hale; Simon Clare; Beatrice Arico; Marzia M Giuliani; Aaron Rae; Alan Huett; Rino Rappuoli; Gordon Dougan; Kingston H G Mills
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

7.  Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland.

Authors:  Margot Mutsch; Weigong Zhou; Philip Rhodes; Matthias Bopp; Robert T Chen; Thomas Linder; Christian Spyr; Robert Steffen
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

8.  Successful induction of protective antibody responses against Haemophilus influenzae type b and diphtheria after transcutaneous immunization with the glycoconjugate polyribosyl ribitol phosphate-cross-reacting material 197 vaccine.

Authors:  Fatme Mawas; Marisa Peyre; Anne-Sophie Beignon; Laura Frost; Giuseppe Del Giudice; Rino Rappuoli; Sylviane Muller; Dorothea Sesardic; Charalambos D Partidos
Journal:  J Infect Dis       Date:  2004-08-11       Impact factor: 5.226

9.  Induction of protective immunity against lethal anthrax challenge with a patch.

Authors:  Richard T Kenney; Jianmei Yu; Mimi Guebre-Xabier; Sarah A Frech; Adam Lambert; Barbara A Heller; Larry R Ellingsworth; James E Eyles; E Diane Williamson; Gregory M Glenn
Journal:  J Infect Dis       Date:  2004-07-13       Impact factor: 5.226

10.  Transcutaneous immunization with tetanus toxoid and mutants of Escherichia coli heat-labile enterotoxin as adjuvants elicits strong protective antibody responses.

Authors:  Rob Tierney; Anne-Sophie Beignon; Rino Rappuoli; Sylviane Muller; Dorothea Sesardic; Charalambos D Partidos
Journal:  J Infect Dis       Date:  2003-08-11       Impact factor: 5.226

View more
  5 in total

1.  Transcutaneous DNA immunization following waxing-based hair depilation elicits both humoral and cellular immune responses.

Authors:  Gang Xiao; Xinran Li; Amit Kumar; Zhengrong Cui
Journal:  Eur J Pharm Biopharm       Date:  2012-07-03       Impact factor: 5.571

2.  Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer.

Authors:  Yen-Lin Huang; Jung-Tung Hung; Sarah K C Cheung; Hsin-Yu Lee; Kuo-Ching Chu; Shiou-Ting Li; Yu-Chen Lin; Chien-Tai Ren; Ting-Jen R Cheng; Tsui-Ling Hsu; Alice L Yu; Chung-Yi Wu; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-25       Impact factor: 11.205

3.  Microneedle-based transcutaneous immunisation in mice with N-trimethyl chitosan adjuvanted diphtheria toxoid formulations.

Authors:  Suzanne M Bal; Zhi Ding; Gideon F A Kersten; Wim Jiskoot; Joke A Bouwstra
Journal:  Pharm Res       Date:  2010-06-18       Impact factor: 4.200

4.  Immune modulation by adjuvants combined with diphtheria toxoid administered topically in BALB/c mice after microneedle array pretreatment.

Authors:  Z Ding; E Van Riet; S Romeijn; G F A Kersten; W Jiskoot; J A Bouwstra
Journal:  Pharm Res       Date:  2009-03-27       Impact factor: 4.200

5.  Super-resolution microscopy unveils transmembrane domain-mediated internalization of cross-reacting material 197 into diphtheria toxin-resistant mouse J774A.1 cells and primary rat fibroblasts in vitro.

Authors:  Maximilian Fellermann; Fanny Wondany; Stefan Carle; Julia Nemeth; Tanmay Sadhanasatish; Manfred Frick; Holger Barth; Jens Michaelis
Journal:  Arch Toxicol       Date:  2020-04-08       Impact factor: 5.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.